Your search for major depressive disorder returned 151 results

Researchers conducted a phase 2 trial to assess the safety and efficacy of single-dose psilocybin treatment for major depressive disorder.

Researchers investigated the all-cause risk for mortality in patients with major depressive disorder exhibiting suicidal behavior.

Researchers analyzed MRI-derived images of participants with mental illness to evaluate the heterogeneity of gray matter volume deviations.

In a systematic review and meta-analysis, estimates for depressive disorders in children younger than 13 years old were evaluated.

Researchers evaluated the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with major depressive disorder.

Researchers evaluated the risk for major depressive disorder among patients with HIV infection.

A study was conducted to determine the effect of mental health disorders on postoperative outcomes following EVAR in patients who are veterans.

Researchers sought to assess how objective cognitive deficits in depression are associated with symptoms, neural circuits, and treatment outcomes.

Some men have said that honest communication and community-based approaches make them more like to engage in mental health care.

The US Preventive Services Task Force (USPSTF) recommends depression screening for all adults and anxiety screening for younger adults.

The FDA has cleared Nexstim’s NBT system for the treatment of major depressive disorder.

Researchers searched for protective effects in gut microbiota from the pathogenesis of major depressive disorder.

Researchers assessed characteristics and correlates of metabolic syndrome in adolescents with major depressive disorder or bipolar disorder depression.

Researchers evaluated the efficacy of dextromorphan-bupropion among patients with major depressive disorder and comorbid anxiety.

The influence of gut microbiota extends to the brain via neuroinflammation, resulting in symptoms associated with major depressive disorder.

Whether major depressive disorder is a comorbidity of bipolar disorder isn’t really known. Researchers built a predictive model of major depressive disorder to bipolar disorder conversion and with the Observational Medical Outcomes Partnership validated the results across a multi-national network of patient databases.

HIV-infected adults with major depressive disorder have a 30% increased risk for acute myocardial infarction.

Adults with major depressive disorder and a history of childhood trauma can still benefit from recommended depression treatments.

Screening recommended for those aged 12 to 18, however there is insufficient evidence to assess for children aged 11 and younger.

Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.

Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.

The researchers sought to examine whether inflammation and white matter microstructure play a role in treatment response in major depressive disorder.

More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder.

The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.

Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.

An additional 53.2 million cases of major depressive disorder and 76.2 million cases of anxiety disorders globally were estimated due to the COVID-19 pandemic.

Researchers seek to evaluate whether trauma-focused therapy adjunctive to treatment as usual (TAU) leads to a greater reduction of depressive symptoms posttreatment vs TAU exclusively in patients with major depressive disorder with childhood trauma.

Researchers compared the white matter networks of patients with remitted major depressive disorder and remitted bipolar disorder to find disease-specific alterations.

AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.

For this study, community-dwelling adults were evaluated for major depressive disorder, generalized anxiety disorder, and global sleep quality over an 18 year period.